Arcitumomab (CEA-Scan®), a F(ab')2 directed against carcinoembryonic antigen (CEA) labelled with 99m-Technetium (99mTc), received FDA and EMEA approval in 1996 for diagnosis of CRC recurrence [4, 5]. This evidence concerns the gene CEACAM5 and colorectal carcinoma.